Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Inclusion Criteria

• Patients must have a gynecologic malignancy or breast cancer (triple negative or hormone receptor positive only) that is refractory/intolerant to all therapies known to confer clinical benefit in the advanced or metastatic setting or if the patient's clinical team and the PI believe that the study treatment gives the patient the best chance for clinical benefit
• Patients with breast cancer must have measurable disease per RECIST 1.1. criteria. Patients with ovarian cancer are eligible with or without measurable disease
• Patients with ovarian cancer must have had appropriate surgical management for their disease and should be platinum resistant (recurrence within 6 months of last platinum-containing regimen) or be refractory to platinum-containing regimens
• Patients with endometrial, cervical, or any other advanced gynecologic malignancy must have already received or not be a candidate for all therapy proven to have a survival benefit
• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
• Patients must be ≥18 years of age
• Patients must have adequate organ function, defined as follows:
• Absolute neutrophil count ≥1,500/µL
• Platelets ≥125,000/µL
• Hemoglobin ≥10 g/dL
• Serum creatinine ≤1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥60 mL/min using the Cockcroft-Gault equation
• Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤1 x ULN
• Aspartate aminotransferase and alanine aminotransferase ≤2.5 x ULN unless liver metastases are present, in which case they must be ≤5 x ULN
• Patient agrees to blood draws during screening and at the end of treatment for molecular and cytogenetic analysis
• Female patients of childbearing potential must have a negative serum pregnancy test (beta hCG) at Screening
• Female patients of childbearing potential must agree to use an acceptable method of birth control (excluding hormonal birth control methods, see Section 3.0.5) for 72 hours prior to initiation of therapy and to continue its use during the study and for at least 180 days after the final dose
• Male patients must agree to use an acceptable form of birth control (see Section 3.0.5) from study Day 1 through at least 180 days after the final dose
• Patients must be able to understand the study procedures and agree to participate in the study by providing written informed consent

Exclusion Criteria

• Patients with HER2+ breast cancer measured by standard IHC or FISH testing
• Patients must not be simultaneously enrolled in any other interventional clinical trial
• Patients must not have had major surgery ≤3 weeks of starting the study and patient must have recovered from any effects of any major surgery
• Patients must not have had investigational therapy administered ≤4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
• Patients must not have had radiotherapy encompassing >20% of the bone marrow
• Patients must not have received prior treatment with a known PARP inhibitor or have participated in a study where any treatment arm included administration of a known PARP inhibitor
• Patients must not have a known hypersensitivity to the components of niraparib, everolimus, rapamycin analogues, or the excipients
• Patients must not be immunocompromised (patients with splenectomy are allowed)
• Patients must not have had any known, persistent >Grade 2 toxicity from prior cancer therapy
• Patients must not have had any known, persistent (>4 weeks), ≥Grade 3 hematological toxicity or fatigue from prior cancer therapy
• Patients must not have received a transfusion (platelets or red blood cells) ≤4 weeks of the first dose of study treatment
• Patients must not have current evidence of any condition, therapy, or laboratory abnormality (including active or uncontrolled myelosuppression [ie, anemia, leukopenia